Sutro Biopharma KOL Event

Virtual, December 3, 2020

General Agenda

KOL Speakers:

Wendel Naumann, MD 
Director, Minimally Invasive Surgery in Gynecologic Oncology
Professor, Department of Ob/Gyn at Atrium Health, Levine Cancer Institute

Lainie P. Martin, MD
Leader, Gynecology/Oncology Program
Associate Professor of Medicine, Hospital at University of Pennsylvania

RSVP for Event / Log Back in

Additional menu options can be found in the menu bar on the left or at the top.

Sutro Biopharma [STRO] US$614 MM MCap
FolR&al­pha;-tar­get­ing ADC (STRO-002) Phase 1, ad­di­tio­n­al dose es­ca­la­tion da­ta in 4Q20. CD74-tar­get­ing ADC (STRO-001) Phase 1, ad­di­tio­n­al dose es­ca­la­tion da­ta in 4Q20. BMS col­lab­o­ra­tion Phase 1 clin­i­cal de­vel­op­ment up­date for CC-99712 (BC­MA-tar­get­ing ADC). Mer­ck col­lab­o­ra­tion up­date in 2020 on first cy­tokine deri­va­tive pro­gram. [more in­for­ma­tion]